Showing 1–25 of 42 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Siamisang K, Rankgoane-Pono G, Madisa TM, Mudiayi TK, Tlhakanelo JT, et al.
…duction Globally, the amount of research on the outcomes of pediatric tuberculosis (TB) is disproportionately less than that of adult TB. The diagnosis of paediatric TB is also problematic in developing countries. The aim of this study was to describe the outcomes of pediatric TB…
Denti P, Wasmann RE, van Rie A, Winckler J, Bekker A, et al.
…pyrazinamide 120/35/130 mg) to children Conclusions Current pediatric FDC doses resulted in low rifampicin exposures. Optimal dosing of all drugs cannot be achieved with the current FDCs. We propose a new FDC formulation and revised weight bands.
Jennifer Cohn, MD, Martina Casenghi, PhD
…ll be conducted in ten countries involved in the Catalyzing Pediatric TB Innovation (CaP-TB) project: Cameroon, Cote D'Ivoire, Democratic Republic of Congo, Kenya, Lesotho, Malawi, Tanzania, Uganda, Zimbabwe and India. The CaP-TB project is a project designed to use innovative me…
Dutta NK, Tornheim JA, Fukutani KF, Paradkar M, Tiburcio RT, et al.
Pediatric tuberculosis (TB) remains a major global health problem. Improved pediatric diagnostics using readily available biosources are urgently needed. We used liquid chromatography-mass spectrometry to analyze plasma metabolite profiles of Indian children with active TB (n = 1…
Heiman F Wertheim, PhD
…ypically have low yield due to the paucibacillary nature of pediatric TB. Culture confirmation may be obtained in as few as 10% of cases of suspected pediatric TB. For these reasons, the true extent of the (drug-resistant) TB epidemic in children is unknown. Thus, either clinicia…
Tae Kyu Chung, Eunsol Yang, Maureen Shin, Belen P Solans, Xujia Zhou, et al.
… **CONCLUSION:** Our IPDMA supports the revision of current pediatric EMB dosing guidelines for the treatment of tuberculosis. Our findings aim to ensure adequate drug exposure across all pediatric weight bands, while also accounting for toxicity and challenges related to formula…
Silvia S. Chiang, Helen E. Jenkins
… 5-year age bands for people <25 years old.In this issue of Pediatrics, Osman et al13 address these research gaps by analyzing the South African Electronic Treatment Register, a national surveillance database of individuals treated for drug-susceptible TB. The study includes ∼85 …
Anna Turkova, Genevieve H. Wills, Eric Wobudeya, Chishala Chabala, Megan Palmer, et al.
…eks) of standard first-line antituberculosis treatment with pediatric fixed-dose combinations as recommended by the World Health Organization. The primary efficacy outcome was unfavorable status (composite of treatment failure [extension, change, or restart of treatment or tuberc…
Harsh Shah, Sandul Yasobant, Jay Patel, Priya Bhavsar, Deepak Saxena, et al.
…uch as drug-sensitive TB (DSTB), drug resistance TB (DRTB), pediatric TB, and extra-pulmonary TB. It included both public and private sector patients. The study's findings suggested that 172 (29%) patients experienced ADRs with at least one symptom. Out of those, 80% had mild sym…
Qian Zhai, Xianglong Kong, Qian Li, Na Yang
… **METHODS:** In this prospective observational study, 235 pediatric pulmonary tuberculosis patients treated at Hebei Provincial Chest Hospital from February 2021 to February 2025 were enrolled. Based on drug-susceptibility testing, participants were classified into a drug-resis…
Apolisi I, Cox H, Tyeku N, Daniels J, Mathee S, et al.
…ment. Key factors supporting these outcomes included use of pediatric formulations for young children, monotherapy, and community-based options for assessment and follow up.
Hamid M, Brooks MB, Madhani F, Ali H, Naseer MJ, et al.
Objective Pakistan has a high pediatric burden of tuberculosis, but few studies describe the treatment experience of children with tuberculosis in Pakistan. We sought to identify risk factors for unsuccessful treatment outcomes in children with drug-susceptible tuberculosis ident…
Yasobant S, Shah H, Bhavsar P, Patel J, Saha S, et al.
…uch as drug-sensitive TB (DSTB), drug resistance TB (DRTB), pediatric TB, and extra-pulmonary TB. It included both public and private sector patients. The study findings suggested that about 41% of pulmonary and 51% of extra-pulmonary patients reported total delay. Delay in initi…
Solans BP, Béranger A, Radtke K, Mohamed A, Mirzayev F, et al.
…ose with HIV are underexposed to RIF. Standardization of PK pediatric studies and individual patient data analysis with safety assessment are needed to inform optimal dosing.
Van Schalkwyk M, Bekker A, Decloedt E, Wang J, Theron GB, et al.
… (PK) of antituberculosis drugs. The International Maternal Pediatric Adolescent AIDS Clinical Trials Network P1026s was a multicenter, phase IV, observational, prospective PK and safety study of antiretroviral and antituberculosis drugs administered as part of clinical care in p…
University of Virginia
…re conversion and weight change are stratified by age given pediatric populations are more likely to be culture negative and clinically diagnosed with weight gain a central measurement of treatment response. Safety of dose adjustment strategy parameters include clinical adverse e…
Nadia Jawad, Nausheen Saifullah, Naseem Ahmed, Saira Jafri
Abstract Aim: To determine the factors associated with persistent sputum positivity at the end of two months of treatment in patients presenting with (drug-susceptible) pulmonary tuberculosis at a tertiary care hospital in Karachi.Setting: A cross-sectional study was conducted at…
Nhat Linh Nguyen, Fuad Mirzayev, Kerri Viney, Medea Gegia, Matteo Zignol
<b>Background:</b> Recent developments in TB treatment have prompted the need for revision of the TB treatment outcome definitions. <b>Aims and objectives:</b> The objectives of the WHO consultation were to determine recent changes in TB treatment affecting treatment outcome defi…
Amit Barua, Joseph Hubble, Kathryn H. Yoo, Michael Lacassagne, John P. Areno, et al.
Recurrence of Pulmonary tuberculosis (TB) after successful completion of supervised treatment may be due to relapse or reinfection. Recurrence is common with an incidence rate of 2.26 per 100 person years over a mean follow up of 2.3 years. However, it is uncommon for an immunoco…
Christopher A. Berger, R. Crowder, A. Kityamuwesi, Noah Kiwanuka, M. Lamunu, et al.
Background: Tuberculosis (TB) treatment completion rates are below global targets. 99DOTS is a low-cost digital adherence technology (DAT) that could increase TB treatment completion. Methods: We conducted a pragmatic, stepped-wedge cluster randomized trial including all adults t…
Nelly Solomonia, K Vacharadze
Georgia has countrywide access to the genotypic and phenotypic drug susceptibility testing (gDST and pDST), however identification of susceptibility to the different anti-Tuberculosis (TB) drugs in different time period, not in all cases gives us opportunity to simultaneously kno…
Nicole Robertson, J. Zachary Porterfield, Alex Kayongo, Bruce Kirenga, Robert Kalyesubula, et al.
Abstract Background Pulmonary tuberculosis (TB) is the leading infectious cause of death globally with an estimated 1.7 billion people currently infected with Mycobacterium tuberculosis and at risk of developing TB. While the treatment of drug-susceptible pulmonary TB is highly e…
M.G. Mustapha, Garba Mohammed Ashir, AI Rabasa, Asmaa Farouk, Hassan Abdullahi Elechi, et al.
Tuberculosis (TB) is an important infectious disease of public health concern. The effects of TB on children in terms of morbidity and mortality is more than that of adults. These may not be unconnected with the differences in characteristics and peculiarities of the disease in c…
Rida Masood, Naeem Muhammad Iyad, Kanwal Ali Sidra, Mushtaque Madiha, Siddiqui Tuba, et al.
This assessment aims to identify the increasing number of morbidity of drug susceptible tuberculosis (TB) and its treatment outcomes, government cost of medicines as well as the economic impact on society. A retrospective observational study had been conducted in a government hos…
Cielo Ríos, Marcela Vásquez Rojas, Martha Lucía Serrano, Alexandra Porras, Ricardo Luque, et al.
We investigated the delays in the diagnosis of tuberculosis and/or HIV, their treatment initiation, and factors associated with each delay. All drug-susceptible tuberculosis cases diagnosed in 2014 and 2015 in Colombia, with a confirmed diagnosis of HIV were included. A total of …